---
---
# Malignant hyperpyrexia (malignant hyperthermia)

**Malignant hyperpyrexia (malignant hyperthermia)** Genetic
susceptibility 1 in 5000 to 1 in 10000, usually autosomal dominant.
Complicates 1 in xxx anaesthetics. Susceptible individuals have on
average had 3 uneventful GAs before diagnosis. Precipitants: volatile
agents, suxamethonium, caffeine, emotional stress. Pathophysiology: loss
of skeletal muscle Ca <sup>++</sup> homeostasis; ryanodine receptor
defect xxx

Management:

*Diagnose:*

\- Masseter spasm (may be only manifestation)

\- Hypermetabolic state:

↑CO<sub>2</sub> ↑HR ↑RR ↑VO<sub>2</sub> ↓ S <sub>P</sub> O<sub>2</sub>

\- Hyperthermia, sweating

\- Unstable BP, arrhythmias.

*Treat:*

1. Get clean circuit, intubate, ventilate 3x normal

2. Give Dantrolene 1-2mg/kg up to 10mg/kg total

\- Decreases Ca++ release from SR.

3. Cooling: cool iv fluid, sponge skin with water

4. Ongoing management:

5. ICU management:

Continue dantrolene for 48hr (prevent retriggering)

Correct hypothermia

Treat pulmonary oedema

Monitor muscle oedema: compartment syndrome

6. Refer pt. To MH centre, Leeds.

\[Halsall, P.J. et al. *BJA CEPD Reviews* **3** , 5-9(2003).\]
